Cash-pay platform brings transparent pricing and direct provider access to first and only oral GLP-1 weight loss medication nationwide
NEW YORK–(BUSINESS WIRE)–Sesame, the leading cash-pay healthcare platform, announced today that it is working with Novo Nordisk as a NovoCare® Recognized Care Provider on the nationwide launch of the new Wegovy® pill. Patients can visit sesamecare.com or use the Sesame mobile app to schedule an appointment with a provider for access to the first and only oral GLP-1 weight loss medication.
“The Wegovy® pill, the first and only FDA-approved oral GLP-1, offers patients a convenient new option for their obesity medicine,” said Dave Moore, Executive Vice President, US Operations, Novo Nordisk. “Our collaboration with Sesame represents another step forward in giving people more choice, with a simple, direct-to-patient path to care designed around individual needs.”
Sesame’s affordability-first model removes insurance carriers and middlemen, delivering transparent, upfront prices that are often far lower than traditional insurance copays or deductibles. Patients choose their own doctor from Sesame’s nationwide network of licensed providers and can book same-day video appointments across all 50 states. With over 1 million patients served to date and a 95 percent satisfaction rating, Sesame is established as a trusted solution for affordable, accessible healthcare.
“This collaboration will bring affordable access to Wegovy® pill representing an opportunity to deliver a breakthrough medicine and accessible care delivery,” said David Goldhill, Sesame CEO and Co-Founder. “Sesame’s direct-to-patient model gives people a simple place to get the care they need, at a price they understand, before they ever book. By providing a simplified experience, we’re ensuring that more Americans can access this revolutionary treatment without navigating confusing rules or facing unexpected costs.”
Sesame offers patients comprehensive weight management support through licensed healthcare providers who can prescribe the Wegovy® pill when clinically appropriate. The platform’s provider network spans primary care physicians, specialists, and nurse practitioners who deliver care both virtually or in-person. Patients can choose their preferred provider and see upfront exactly how much they will pay for video visits and unlimited messaging with their chosen clinician.
Sesame’s comprehensive weight loss program starts at $99/month and includes ongoing video care and messaging with a dedicated provider, labs to monitor progress, and support for healthier habits around diet, exercise, and sleep. Separately, the program accepts insurance for GLP-1 medications and other weight loss treatments, while also offering affordable self-pay options. Patients can choose from a range of FDA-approved drugs, including Wegovy® pill and Wegovy® pen, with medication costs starting as low as $25/month for commercially insured patients or $149/month for self-pay patients.
For more information on Sesame’s weight management services and full suite of healthcare options, visit sesamecare.com.
About Sesame
Sesame is the only cash-pay healthcare platform connecting patients directly with top-rated doctors at transparent, upfront prices. By removing insurance, Sesame unlocks lower cost, more convenient access to high-quality clinicians for everyday care. Since 2019, Sesame has served over 1 million patients across all 50 states, offering more than 380 services including primary care, mental health, dermatology, weight management, and pediatrics. Founded by David Goldhill, Michael Botta, PhD, and John Fontein, Sesame has raised $90 million in funding, including a 2022 Series B round led by Google Ventures. For more information, visit sesamecare.com.
Contacts
Press:
Kari Porter
[email protected]
